Seeking men and women who are experiencing recurring fluid buildup in their abdomen due to liver cirrhosis for a study of an implanted investigational device to drain the excess fluid.
2 Studies found
Reverse: A Study Of An Investigational Drug For Compensated Cirrhosis Due To Nonalcoholic Steatohepatitis (Nash)
Nonalcoholic Steatohepatitis (NASH) results when fat accumulates in the liver and causes inflammation and scarring called fibrosis. Fibrosis can lead to cirrhosis which impairs liver function. Ocaliva (OCA) is an FDA approved drug for treating another type of liver disease. This study will test if Ocaliva (OCA) is safe and effective in treating cirrhosis of the liver caused by advanced NASH.